Mentice AB (SE:MNTC)
:MNTC
Top Page
Mentice AB
(MNTC)
Select Model
Select Model
Rating:56Neutral
Price Target:
kr13.50
▲(0.75% Upside)
Action:ReiteratedDate:03/02/26
The score is held back primarily by weak financial performance—persistent losses, margin volatility, and a return to cash burn in 2025—despite a relatively serviceable balance sheet. Technicals are a meaningful offset with a bullish trend (price above key moving averages and positive MACD). Valuation remains constrained because earnings are negative and no dividend yield is provided.
Positive Factors
Recurring and diversified revenue streams
Mentice’s business model combines system sales with software licensing, subscriptions, maintenance and add-on modules plus work with device companies. That mix creates recurring revenue, upsell paths and customer stickiness, supporting steadier cash flows and predictable revenue over multiple quarters.
Negative Factors
Persistent net losses and margin volatility
Sustained losses and volatile margins—culminating in a sharp 2025 deterioration—erode retained earnings and limit internal funding for growth. Weak profitability reduces capacity to scale commercial efforts, worsens return on invested capital, and raises reliance on external financing for strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring and diversified revenue streams
Mentice’s business model combines system sales with software licensing, subscriptions, maintenance and add-on modules plus work with device companies. That mix creates recurring revenue, upsell paths and customer stickiness, supporting steadier cash flows and predictable revenue over multiple quarters.
Read all positive factors
Mentice AB (MNTC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr362.82M
Dividend YieldN/A
Average Volume (3M)19.32K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-0.02%
EPS Growth-85.98%
CountrySE
Employees131
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.46
Shares Outstanding28,125,734
10 Day Avg. Volume26,429
30 Day Avg. Volume19,315
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)2.71
Price to Sales (P/S)1.34
P/FCF Ratio-14.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.09
Revenue Forecast (FY)kr308.01M
Mentice AB Business Overview & Revenue Model
Company Description
Mentice AB (publ) provides endovascular simulation solutions to teaching entities, healthcare systems, and medical device manufacturers. The company operates through Medical Device Industry, Healthcare Systems, and Strategic Alliances segments. It...
How the Company Makes Money
Mentice makes money primarily by selling and licensing simulation solutions used for interventional procedure training and planning. Key revenue streams typically include: (1) sales of simulation systems that bundle proprietary software with compa...
Mentice AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
39
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 279.09M | 290.33M | 273.61M | 217.95M | 185.06M |
| Gross Profit | -33.06M | 257.25M | 236.38M | 188.94M | 149.92M |
| EBITDA | -1.72M | 18.30M | 28.87M | 266.00K | 1.44M |
| Net Income | -32.33M | -18.42M | -2.82M | -30.66M | -29.19M |
Balance Sheet | |||||
| Total Assets | 312.02M | 323.90M | 322.53M | 332.98M | 261.90M |
| Cash, Cash Equivalents and Short-Term Investments | 33.38M | 53.59M | 59.12M | 47.28M | 12.70M |
| Total Debt | 26.15M | 9.14M | 9.56M | 16.68M | 14.70M |
| Total Liabilities | 173.65M | 180.24M | 163.55M | 170.34M | 125.02M |
| Stockholders Equity | 138.38M | 143.66M | 158.97M | 162.63M | 136.89M |
Cash Flow | |||||
| Free Cash Flow | -25.43M | 1.48M | 29.53M | 1.85M | -31.03M |
| Operating Cash Flow | -20.30M | 17.92M | 36.52M | 14.91M | -5.13M |
| Investing Cash Flow | -15.46M | -16.44M | -16.18M | -32.28M | -25.90M |
| Financing Cash Flow | 19.66M | -9.31M | -7.05M | 48.99M | -5.78M |
Mentice AB Technical Analysis
Negative
13.40
Price Trends
13.56
Negative
13.70
Negative
13.18
Negative
Market Momentum
-0.16
Positive
39.86
Neutral
7.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MNTC, the sentiment is Negative. The current price of 13.4 is above the 20-day moving average (MA) of 13.37, below the 50-day MA of 13.56, and above the 200-day MA of 13.18, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 39.86 is Neutral, neither overbought nor oversold. The STOCH value of 7.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MNTC.
Mentice AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr362.82M | -11.61 | -27.25% | ― | -0.02% | -85.98% | |
55 Neutral | kr904.95M | 168.74 | 6.93% | ― | -5.80% | -65.99% | |
55 Neutral | kr276.41M | -4.05 | -27.22% | ― | 16.38% | 35.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr321.27M | -6.28 | -104.38% | ― | 21.88% | 48.86% | |
46 Neutral | kr576.47M | -88.91 | -2.52% | ― | -8.10% | 62.08% | |
44 Neutral | kr151.00M | -4.28 | -61.62% | ― | 14.18% | 72.73% |
* Healthcare Sector Average
SE:MNTC
Mentice AB
12.90
-5.79
-30.96%
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.65
1.66
55.26%
SE:BACTI.B
Bactiguard Holding AB
17.20
-12.70
-42.47%
SE:CRAD.B
C-Rad AB Class B
27.00
-2.50
-8.47%
SE:ACARIX
Acarix AB
0.28
0.05
20.17%
SE:BRAIN
BrainCool AB
0.72
-1.06
-59.48%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.